Since PKM2 and GLS1 separately are two important rate-limiting enzymes in aerobic glycolysis and glutaminolysis [26, 27], we in the present study sought to investigate the possible contributory role of PKM2 and GLS1 expression in oxaliplatin-resistance CRC. The gene discussed is PKM; the disease is colorectal carcinoma.